ArvCon, now in its seventh year, is a weekend featuring multiple tabletop roleplaying game sessions, a concert, giveaways, and other surprises, benefiting the Damon Runyon Cancer Research Foundation. Damon Runyon’s award programs are targeted to have the greatest impact on cancer research, providing critical early career support to researchers pursuing work with a high potential to impact all types of cancer. Damon Runyon’s mission is to foster new generations of elite scientists and fill gaps in traditional research funding that threaten future breakthroughs.
Damon Runyon News
Five scientists with exceptional promise and novel approaches to fighting cancer have been named the 2021 recipients of the Damon Runyon Physician-Scientist Training Award. The awardees were selected through a highly competitive and rigorous process by a scientific committee comprised of leading cancer researchers who are themselves physician-scientists.
In addition to his Damon Runyon-funded research project, which aims to optimize the delivery of the chemotherapy drug cisplatin, Quantitative Biology Fellow Vitor Mori, PhD, has dedicated some of his efforts over the past year to addressing the COVID-19 crisis in his home city of Sao Paulo, Brazil. The most populous city in the Western and Southern hemispheres, Sao Paolo has been struck particularly hard by the pandemic – Brazil’s COVID-19 death toll is second only to the United States.
While some cancers are known to be caused by mutations in key genes, genetic mutation does not always tell the full story. Epigenetic changes—which do not affect the DNA sequence itself, but rather the degree to which a gene is expressed—can play an important role in cancer as well. Such is the case with acute lymphoblastic leukemia (ALL), the most common form of cancer in children, which has a low incidence of genetic mutation but often coincides with abnormal epigenetic behavior.
There are two types of genes that, if mutated, can lead to cancer. One set of genes directs cell growth – a mutation in one of these genes can cause cells to grow uncontrollably, like a gas pedal stuck to the car floor. The other set of genes function as the “brakes,” telling cells when to slow down, correct replication mistakes, or undergo apoptosis (programmed cell death). These are called tumor suppressor genes, and as the name implies, a disruption in their function can allow the growth of tumors.
Established by an Act of Congress in 1863, the National Academy of Sciences (NAS) is the body of distinguished researchers “charged with providing independent, objective advice to the nation on matters related to science and technology.” Election to membership is among the highest honors a scientist can receive. This year, three Damon Runyon alumni join the NAS ranks, bringing the total number of Damon Runyon alumni in NAS to 89.
By the time patients experience symptoms, their tumors contain a genetically diverse collection of cancer cells, each with an accumulation of mutations. If we could better understand the sequence of events that leads from a single mutation to a heterogeneous population of tumor cells, earlier detection and intervention might be possible. However, attempts to trace this evolution where it has already occurred (in model organisms, immortalized cell lines, or patient samples) face significant challenges.
The second class of Damon Runyon Quantitative Biology Fellows, announced this month, will apply the tools of computational biology to generate and interpret cancer research data at extraordinary scale and resolution. From RNA sequencing data that pinpoints tumor cells to their exact location to three-dimensional models of cell-cell interaction, their projects extend the boundaries of what is possible in cancer research, allowing them to tackle fundamental biological and clinical questions.
The KRAS gene, responsible for encoding a protein that serves as an “on/off” switch for cell growth, is one of the most commonly mutated genes in cancer. The frequency and nature of its mutation differ across cancer types, however, with the highest occurrence of mutation found in cancers of the colorectum, pancreas, lung, and blood plasma.
The American Association for Cancer Research (AACR) is the oldest and largest cancer research organization in the world. Its Fellows, selected through a rigorous peer review process, are scientists from a range of disciplines whose work has “propelled significant innovation and progress against cancer.”